Erik A. Bey

4.8k citations

35 papers · 4.0k indexed · 2 hit papers · h-index 26

Impact in

Toxicology top 0.05%
- Bioactive Compounds and Antitumor Agents
Biomaterials top 1%
- Nanoparticle-Based Drug Delivery

Papers in

Toxicology 22
- Bioactive Compounds and Antitumor Agents 22
Molecular Biology 29
- Cancer therapeutics and mechanisms 16
- DNA Repair Mechanisms 4
- Genomics, phytochemicals, and oxidative stress 3

Co-authors: David A. Boothman Jinming Gao Ying Dong Chalermchai Khemtong Jagadeesh Setti Guthi Jimin Ren A. Dean Sherry Hua Ai
Journals: Cancer Research (8 papers)Clinical Cancer Research (4 papers)Journal of Biological Chemistry (2 papers)Molecular Cancer Therapeutics (1 paper)International Journal of Radiation Oncology*Biology*Physics (1 paper)
Partner nations: United States United Kingdom France

In The Last Decade

Erik A. Bey

35 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases 2013 · 472 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Critical Reviews in Eukaryotic Gene Expression
2006 Nano Letters

Peers

Countries citing papers authored by Erik A. Bey

Since Specialization

Citations

This map shows the geographic impact of Erik A. Bey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik A. Bey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik A. Bey more than expected).

Fields of papers citing papers by Erik A. Bey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik A. Bey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik A. Bey. The network helps show where Erik A. Bey may publish in the future.

Co-authors

The 25 scholars most cited alongside Erik A. Bey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Erik A. Bey Line = papers co-authored together Erik A. Bey links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer Genes ·Brian Madajewski, N S Sorci, Iván Martínez, Julia H. Carter, Erik A. Bey	2023	5
2	Single-Cell Kinetic Modeling of β-Lapachone Metabolism in Head and Neck Squamous Cell Carcinoma Antioxidants ·Biagio John Melloni, Cristina M. Furdui, Erik A. Bey, Melissa L. Kemp	2023	2
3	Y Chromosome LncRNA Are Involved in Radiation Response of Male Non–Small Cell Lung Cancer Cells Cancer Research ·Núbia Idalete Alves Dantas Gabriel, Mariusz Strzeżek, Lei, Артур Юрьевич Малыгин, Murillo Sapia Gutier, 王轶倩, 禎堀田, M Avenel-Audran, Karen E. Hayes, Samuel A. Sprowls, María Estévez Narváez, E Charbon, Erik A. Bey, Daniel A. Finch-Race, Zuan-Fu Lim, Lin Zhu, Sijin Wen, Gangqing Hu, C. Patrick, Iván Martínez	2020	35
4	NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers Clinical Cancer Research ·Edward A. Motea, Xiumei Huang, O Troglia, Jessica A. Kilgore, Noelle S. Williams, Xian‐Jin Xie, David E. Gerber, Muhammad Shaalan Beg, Erik A. Bey, David A. Boothman	2019	33
5	Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC Molecular Cancer Research ·Brian Madajewski, N S Sorci, Gaurab Chakrabarti, David A. Boothman, Erik A. Bey	2015	50
6	Tumor-Selective, Futile Redox Cycle-Induced Bystander Effects Elicited by NQO1 Bioactivatable Radiosensitizing Drugs in Triple-Negative Breast Cancers Antioxidants and Redox Signaling ·Lifen Cao, Long Shan Li, Chai Chew Yian, Ling Xiao, Gaurab Chakrabarti, Erik A. Bey, Kathryn E. Reinicke, Melissa C. Srougi, Zachary Moore, Ying Dong, Enilene Regina Lovatte, Wareef Kabbani, Chin-Rang Yang, Xiaoyu Wang, Farjana Fattah, Julio C. Morales, Edward A. Motea, William G. Bornmann, John S. Yordy, David A. Boothman	2014	32
7	Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers Molecular Cancer Therapeutics ·Erik A. Bey, Kathryn E. Reinicke, Melissa C. Srougi, Marie E. Varnes, Vernon Anderson, John J. Pink, Long Shan Li, Malina Patel, Lifen Cao, Zachary Moore, Amy Rommel, N S Sorci, Cheryl Lewis, David Euhus, William G. Bornmann, Donald J. Buchsbaum, Douglas R. Spitz, Jinming Gao, David A. Boothman	2013	84
8	Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases Critical Reviews in Eukaryotic Gene Expression ·Julio C. Morales, Long-Shan Li, Farjana Fattah, Ying Dong, Erik A. Bey, Malina Patel, Jinming Gao, David A. Boothman Hit paper breakdown →	2013	472
9	Hemoglobin-Based Oxygen Carrier Mitigates Transfusion-Mediated Pancreas Cancer Progression Annals of Surgical Oncology ·Su Wen, Erik A. Bey, Nalan KOLUMAN, Bianca Weder, David A. Boothman, Christopher C. Silliman, Carlton C. Barnett	2013	6
10	An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis Cancer Research ·Xiumei Huang, Ying Dong, Erik A. Bey, Jessica A. Kilgore, Joseph S. Bair, Long-Shan Li, Malina Patel, Elizabeth I. Parkinson, Yiguang Wang, Noelle S. Williams, Jinming Gao, Paul J. Hergenrother, David A. Boothman	2012	119
11	Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy Clinical Cancer Research ·Long Shan Li, Erik A. Bey, Ying Dong, Jieru Meng, Biswanath Patra, Jingsheng Yan, Xian‐Jin Xie, Rolf A. Brekken, Carlton C. Barnett, William G. Bornmann, Jinming Gao, David A. Boothman	2011	94
12	Prostate Cancer Radiosensitization through Poly(ADP-Ribose) Polymerase-1 Hyperactivation Cancer Research ·Ying Dong, Erik A. Bey, Long-Shan Li, Wareef Kabbani, Jingsheng Yan, Xian‐Jin Xie, Jer‐Tsong Hsieh, Jinming Gao, David A. Boothman	2010	75
13	β-Lapachone Micellar Nanotherapeutics for Non–Small Cell Lung Cancer Therapy Cancer Research ·Elvin Blanco, Erik A. Bey, Chalermchai Khemtong, Y. Al-Ashqa, Rizwan Mohammed, Huabing Chen, Chase W. Kessinger, Kevin Carnevale, William G. Bornmann, David A. Boothman, Jinming Gao	2010	115
14	Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations Cancer Research ·Georgia Konstantinidou, Erik A. Bey, Andrea Rabellino, Katja Schuster, Kattia Sarai Sangama Estrada, Adi F. Gazdar, Augusto Amici, David A. Boothman, Pier Paolo Scaglioni	2009	124
15	In vivo Off-Resonance Saturation Magnetic Resonance Imaging of αvβ3-Targeted Superparamagnetic Nanoparticles Cancer Research ·Chalermchai Khemtong, Chase W. Kessinger, Jimin Ren, Erik A. Bey, Y. Al-Ashqa, Jagadeesh Setti Guthi, David A. Boothman, A. Dean Sherry, Jinming Gao	2009	81
16	Nonhomologous End Joining Is Essential for Cellular Resistance to the Novel Antitumor Agent, β-Lapachone Cancer Research ·Melissa S. Bentle, Kathryn E. Reinicke, Ying Dong, Erik A. Bey, David A. Boothman	2007	63
17	Mornings with art, lessons learned: Feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses Journal of Cellular Physiology ·Erik A. Bey, Shelly M. Wuerzberger‐Davis, John J. Pink, Chin‐Rang Yang, Shinako Araki, Kathryn E. Reinicke, Melissa S. Bentle, Ying Dong, M. C. L., Tracy Criswell, Mark W. Wagner, Longshan Li, Jinming Gao, David A. Boothman	2006	22
18	Efficacy of beta-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1 Cancer Biology & Therapy ·Chong Jai Kim, Anne Marie Lewis, Erik A. Bey, Jinming Gao, Justine M. Ritchie, William G. Bornmann, David A. Boothman, Larry W. Oberley, Joseph J. Cullen	2005	155
19	Antisense Oligodeoxyribonucleotides: A Better Way to Inhibit Monocyte Superoxide Anion Production? Methods in enzymology on CD-ROM/Methods in enzymology ·Erik A. Bey, Martha K. Cathcart	2002	6
20	Phenotypic differences among morphologically similar small-cell carcinomas detected with a panel of monoclonal antibodies and indirect immunofluorescence and flow cytometry International Journal of Cancer ·Aurelia M. C. Koros, Erik A. Bey, 大西圭一, I. Văduva	1994	2

About Erik A. Bey

Erik A. Bey is a scholar working on Toxicology, Molecular Biology, Organic Chemistry, Biomaterials and Oncology, having authored 35 papers that have together received 4.0k indexed citations. Recurring topics across this work include Bioactive Compounds and Antitumor Agents (22 papers), Cancer therapeutics and mechanisms (16 papers), Synthesis and Biological Evaluation (6 papers), DNA Repair Mechanisms (4 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (4 papers), Nanoparticle-Based Drug Delivery (4 papers), PARP inhibition in cancer therapy (4 papers) and Genomics, phytochemicals, and oxidative stress (3 papers). The work is most often cited by research in Toxicology (1.0k citations), Biomaterials (1.1k citations), Organic Chemistry (971 citations), Physiology (134 citations) and Molecular Biology (1.9k citations). Erik A. Bey has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include David A. Boothman, Jinming Gao, Ying Dong, Chalermchai Khemtong, Jagadeesh Setti Guthi, Jimin Ren, A. Dean Sherry, Hua Ai, Norased Nasongkla and Kathryn E. Reinicke. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Journal of Biological Chemistry, Molecular Cancer Therapeutics and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact